Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.

Saved in:
Bibliographic Details
Title: Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer.
Authors: Aredo JV; Department of Medicine, University of California, San Francisco, CA, 94143, USA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Wakelee HA; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Hui AB; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Padda SK; Division of Oncology, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA., Joshi ND; University Healthcare Alliance, Stanford Healthcare, Newark, CA, 94560, USA., Guo HH; Department of Radiology, Stanford University School of Medicine, Stanford, CA, 94305, USA., Chaudhuri A; Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, 63110, USA., Diehn M; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Loo BW Jr; Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA., Neal JW; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA. Electronic address: jwneal@stanford.edu.
Source: Cancer treatment and research communications [Cancer Treat Res Commun] 2022; Vol. 33, pp. 100659. Date of Electronic Publication: 2022 Nov 17.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101694651 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2468-2942 (Electronic) Linking ISSN: 24682942 NLM ISO Abbreviation: Cancer Treat Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2468-2942
DOI:10.1016/j.ctarc.2022.100659